The finding of functionally significant mutations in plexinB1 in prostate tumours and overexpression of the plexinB1 protein suggests that plexinB1 has a role in prostate cancer and so is a potential target for therapy. This evidence concerns the gene PLXNB1 and prostate carcinoma.